Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0030 in Advanced Solid Tumors
NCT05706207Phase 1Unknown
- Sponsor
- Huabo Biopharm
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HB0030 in solid tumor (advanced stage), sponsored by Huabo Biopharm. Primary endpoints: Dose Limiting Toxicity up to 21 days and Maximum Tolerated Dose up to 24 Months. Status: unknown.
02
Drugs
HB0030
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05706207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05706207.